Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate

NCT01500278 is registered in ClinicalTrials.gov with UCB Pharma SA as lead sponsor.

NCT NCT01500278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01500278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate
Lead sponsor
UCB Pharma SA
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2011
Completion date
January 31, 2016
Enrollment
915 (actual)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis